Aerpio Story

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:4em;'>AP</div>
ARPO -- USA Stock  

USD 1.49  0.05  3.47%

In general, we focus on analyzing Aerpio (NASDAQ:ARPO) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aerpio Pharmaceuticals daily price indicators and compare them against related drivers. My story will outline Aerpio Pharmaceuticals. We will evaluate why recent Aerpio Pharmaceuticals price moves suggest a bounce in September.
Published over a month ago
View all stories for Aerpio Pharmaceuticals | View All Stories
Is Aerpio Pharmaceuticals (NASDAQ:ARPO) gaining more confidence from institutional investors?
We provide trade advice to complement the prevailing expert consensus on Aerpio Pharmaceuticals. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. About 24.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.97. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aerpio Pharmaceuticals recorded a loss per share of 0.46. The entity had not issued any dividends in recent years.
The successful prediction of Aerpio Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Aerpio Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Aerpio Pharmaceuticals based on Aerpio Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Aerpio Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Aerpio Pharmaceuticals's related companies.

Watch out for price decline

Please consider monitoring Aerpio Pharmaceuticals on a daily bases if you are holding a position in it. Aerpio Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Aerpio Pharmaceuticals stock to be traded above the $1 level to remain listed. If Aerpio Pharmaceuticals stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

Use Technical Analysis to project Aerpio expected Price

Aerpio Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Aerpio Pharmaceuticals technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Aerpio Pharmaceuticals trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Aerpio utilizes its cash?

To perform a cash flow analysis of Aerpio Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Aerpio Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Aerpio Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Aerpio Pharmaceuticals Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (24.48 Million)

Acquisition by Dugel Pravin of 52144 shares of Aerpio Pharmaceuticals subject to Rule 16b-3

Legal trades by Aerpio Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Aerpio insider trading alert for grant of stock option (right to buy) by Dugel Pravin, the corporate stakeholder, on 26th of June 2020. This event was filed by Aerpio Pharmaceuticals In with SEC on 2020-06-26. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down the case for Aerpio Pharmaceuticals

This firm reported the previous year's revenue of 2.14 K. Net Loss for the year was (18.7 M) with profit before overhead, payroll, taxes, and interest of 20.16 M.
 2019 2020 (projected)
Interest Expense121.65 K179.12 K
Gross Profit18.14 M18.04 M

Revenues Breakdown

Aerpio Pharmaceuticals Revenues yearly trend continues to be quite stable with very little volatility. The value of Revenues is projected to decrease to about 18 M. Revenues usually refers to amount of Revenue recognized from goods sold; services rendered; insurance premiums; or other activities that constitute an earning process. Interest income for financial institutions is reported net of interest expense and provision for credit losses. Aerpio Pharmaceuticals Revenues is quite stable at the moment as compared to the past year. The company's current value of Revenues is estimated at 18.04 Million
2010
2019
2020
201020.16 Million
201918.14 Million
202018.04 Million

Will Aerpio institutional investors exit after the slide?

Aerpio Pharmaceuticals latest mean deviation surges over 4.31. Aerpio Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Aerpio Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Aerpio Pharmaceuticals volatility.

The Current Takeaway on Aerpio Pharmaceuticals Investment

Whereas many other companies in the biotechnology industry are either recovering or due for a correction, Aerpio Pharmaceuticals may not be performing as strong as the other in terms of long-term growth potentials. With a less-than optimistic outlook for your 30 days horizon, it may be a good time to trade some or all of your Aerpio Pharmaceuticals holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Aerpio Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Aerpio Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com